What is the recommended dosage of FRUZAQLA?

The recommended dose of FRUZAQLA is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take FRUZAQLA with or without food at approximately the same time each day.

What should a patient do if a dose of FRUZAQLA is missed?

Take a missed dose if less than 12 hours have passed since the missed scheduled dose. Do not take two doses on the same day to make up for a missed dose.

What is the recommended dosing cycle?

Days 1-21: One 5mg capsule of FRUZAQLA, once daily by mouth. Days 22-28: Treatment break. After Day 28, Begin a new treatment cycle with the same schedule. Continue treatment until disease progression or unacceptable toxicity occurs.

Convenient, once-daily oral dosing with FRUZAQLA^® (fruquintinib)¹

From dosing to missed-dose management, FRUZAQLA follows a straightforward administration schedule:

One pill taken once daily.¹

5 mg and 1 mg capsules can be taken with or without food and should be swallowed whole.¹

Missed doses may be taken within 12 hours of the scheduled time, but 2 doses should not be taken on the same day.¹

Recommended dosage of FRUZAQLA follows a 28-day cycle:

Days 1-21: One 5mg capsule of FRUZAQLA, once daily by mouth

Days 22-28: Treatment break

After Day 28, Begin a new treatment cycle with the same schedule
Continue treatment until disease progression or unacceptable toxicity occurs.

Create a customized FRUZAQLA dosing calendar for your patients

Please select your patient’s expected start date and the subsequent treatment cycle dates will automatically populate in the calendar.

Tap the start date to begin.

Enter the dates of your treatment to download your dosing calendar

Clear dose reductions can help manage ARs¹

Recommended dose reductions

FRUZAQLA is available in either 1 mg or 5 mg capsules. Talk to your patients about which capsule is right for them based on the dosage administered.

Neither mild hepatic impairment nor renal impairment (any severity) requires dose adjustment.

Resources for healthcare professionals

Learn more about resources to help support your practice.

Find support and resources

Ordering FRUZAQLA

Find information on how to order FRUZAQLA for your patients, including distribution and access details.

Start your order

ARs=adverse reactions.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypertension occurred in 49% of 911 patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly for the first month and at least monthly thereafter as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on severity of hypertension.

Hemorrhagic Events including serious, fatal events can occur with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced gastrointestinal hemorrhage, including 1% with a Grade ≥3 event and 2 patients with fatal hemorrhages. Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants.

Infections. FRUZAQLA can increase the risk of infections, including fatal infections. In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%). Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. Resume FRUZAQLA at the same dose when the infection has resolved.

Gastrointestinal Perforation occurred in patients treated with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 1.3% experienced a Grade ≥3 gastrointestinal perforation, including one fatal event. Permanently discontinue FRUZAQLA in patients who develop gastrointestinal perforation or fistula.

Hepatotoxicity. FRUZAQLA can cause liver injury. In 911 patients with mCRC treated with FRUZAQLA, 48% experienced increased ALT or AST, including Grade ≥3 events in 5%, and fatal events in 0.2% of patients. Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically throughout treatment with FRUZAQLA. Temporarily hold and then reduce or permanently discontinue FRUZAQLA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests.

Proteinuria. FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade ≥3 events. Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria ≥2g/24 hours, withhold FRUZAQLA until improvement to ≤Grade 1 proteinuria and resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome.

Palmar-Plantar Erythrodysesthesia (PPE) occurred in 35% of 911 patients treated with FRUZAQLA, including 8% with Grade 3 events. Based on severity of PPE, withhold FRUZAQLA and then resume at the same or reduced dose.

Posterior Reversible Encephalopathy Syndrome (PRES), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one of 911 patients treated with FRUZAQLA. Perform an evaluation for PRES in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue FRUZAQLA in patients who develop PRES.

Impaired Wound Healing. In 911 patients with mCRC treated with FRUZAQLA, 1 patient experienced a Grade 2 event of wound dehiscence. Do not administer FRUZAQLA for at least 2 weeks prior to major surgery. Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established.

Arterial Thromboembolic Events. In 911 patients with mCRC treated with FRUZAQLA, 0.8% of patients experienced an arterial thromboembolic event. Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. In patients who develop arterial thromboembolism, discontinue FRUZAQLA.

Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF). FRUZAQLA 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. FRUZAQLA 1 mg contains FD&C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.

Embryo-Fetal Toxicity. Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥20%) following treatment with FRUZAQLA included hypertension, palmar-plantar erythrodysesthesia (hand-foot skin reactions), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.

DRUG INTERACTIONS

Avoid concomitant administration of FRUZAQLA with strong or moderate CYP3A inducers.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose.

Females and Males of Reproductive Potential

Pregnancy Testing: Verify pregnancy status of females of reproductive potential prior to initiating FRUZAQLA.
Contraception: Females of childbearing potential and males with female partners of childbearing potential should use effective contraception during treatment and for 2 weeks after the last dose of FRUZAQLA.
Infertility: Advise females of reproductive potential that FRUZAQLA may cause post-implantation loss.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see FRUZAQLA (fruquintinib) full Prescribing Information.

Convenient, once-daily oral dosing with FRUZAQLA^® (fruquintinib)¹

From dosing to missed-dose management, FRUZAQLA follows a straightforward administration schedule:

Recommended dosage of FRUZAQLA follows a 28-day cycle:

Create a customized FRUZAQLA dosing calendar for your patients

Enter the dates of your treatment to download your dosing calendar

Clear dose reductions can help manage ARs¹

Recommended dose reductions

Neither mild hepatic impairment nor renal impairment (any severity) requires dose adjustment.

Resources for healthcare professionals

Ordering FRUZAQLA

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION

From dosing to missed-dose management, FRUZAQLA follows a straightforward administration schedule:

Recommended dosage of FRUZAQLA follows a 28-day cycle:​

Create a customized FRUZAQLA dosing calendar for your patients

Enter the dates of your treatment to download your dosing calendar

Clear dose reductions can help manage ARs1

Recommended dose reductions

Neither mild hepatic impairment nor renal impairment (any severity) requires dose adjustment.

Resources for healthcare professionals

Ordering FRUZAQLA

IMPORTANT SAFETY INFORMATION AND INDICATION

Recommended dosage of FRUZAQLA follows a 28-day cycle:

Clear dose reductions can help manage ARs¹